Chugai Pharmaceutical Co., Ltd. (CHGCY)

Chugai Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	403,958	458,674	222,169	267,753	212,333	203,941
Short-Term Investments	441,360	280,308	280,938	204,217	166,287	129,117
Cash & Short-Term Investments	845,318	738,982	503,107	471,970	378,620	333,058
Cash Growth	36.61%	46.88%	6.60%	24.66%	13.68%	33.55%
Accounts Receivable	326,651	318,892	512,538	355,081	253,342	181,641
Other Receivables	1,203	1,456	1,745	928	12	-
Receivables	327,854	320,348	514,283	356,009	253,354	181,641
Inventory	273,197	273,480	292,206	208,838	183,893	168,122
Prepaid Expenses	-	21,827	18,770	17,301	14,997	11,807
Other Current Assets	34,691	11,789	8,171	9,543	4,042	5,052
Total Current Assets	1,481,060	1,366,426	1,336,537	1,063,661	834,906	699,680
Property, Plant & Equipment	435,686	420,701	386,651	352,107	297,490	265,308
Long-Term Investments	-	61,086	56,185	44,663	31,287	27,708
Other Intangible Assets	20,824	19,860	25,141	21,974	23,880	23,540
Long-Term Deferred Tax Assets	64,243	64,474	65,244	56,287	47,934	42,680
Other Long-Term Assets	67,923	-	-	2	1	-1
Total Assets	2,069,736	1,932,547	1,869,758	1,538,694	1,235,498	1,058,915
Accounts Payable	76,294	112,468	209,835	152,266	100,396	77,635
Accrued Expenses	-	44,629	37,751	34,421	31,575	28,690
Current Portion of Leases	-	6,975	6,434	6,550	6,649	7,263
Current Income Taxes Payable	67,655	71,573	121,160	108,293	83,313	58,576
Current Unearned Revenue	-	31	79	86	80	252
Other Current Liabilities	107,497	52,541	48,471	25,806	14,057	6,852
Total Current Liabilities	251,446	288,217	423,730	327,422	236,070	179,268
Long-Term Leases	-	6,480	7,675	9,490	4,635	5,489
Long-Term Deferred Tax Liabilities	4,831	5,787	7,086	7,614	9,166	9,304
Other Long-Term Liabilities	8,217	3,337	3,569	3,206	3,342	3,775
Total Liabilities	268,369	306,967	445,371	350,677	255,495	204,930
Common Stock	73,202	73,202	73,202	73,202	73,202	73,016
Additional Paid-In Capital	69,783	69,355	68,806	68,223	67,586	67,037
Retained Earnings	1,651,255	1,488,738	1,293,352	1,054,050	849,093	722,076
Comprehensive Income & Other	7,127	-5,715	-10,973	-7,458	-9,878	-8,144
Total Common Equity	1,801,367	1,625,580	1,424,387	1,188,017	980,003	853,985
Shareholders' Equity	1,801,367	1,625,580	1,424,387	1,188,017	980,003	853,985
Total Liabilities & Equity	2,069,736	1,932,547	1,869,758	1,538,694	1,235,498	1,058,915
Total Debt	-	13,455	14,109	16,040	11,284	12,752
Net Cash (Debt)	845,318	725,527	488,998	455,930	367,336	320,306
Net Cash Growth	36.61%	48.37%	7.25%	24.12%	14.68%	28.55%
Net Cash Per Share	513.67	440.92	297.20	277.12	223.29	194.77
Filing Date Shares Outstanding	1,646	1,645	1,645	1,644	1,644	1,643
Total Common Shares Outstanding	1,646	1,645	1,645	1,644	1,644	1,643
Working Capital	1,229,614	1,078,209	912,807	736,239	598,836	520,412
Book Value Per Share	1094.71	988.01	865.88	722.50	596.16	519.91
Tangible Book Value	1,780,543	1,605,720	1,399,246	1,166,043	956,123	830,445
Tangible Book Value Per Share	1082.06	975.94	850.59	709.13	581.63	505.58

Source: S&P Capital IQ. Standard template. Financial Sources.